Meeting
2019 Genitourinary Cancers Symposium
Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.
Authors
Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Catherine Handy Marshall , Andrea McNatty , Mario A. Eisenberger , Alan Haruo Bryce , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 154)
DOI
10.1200/JCO.2019.37.7_suppl.154
Abstract #
154
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin
Poster
2023 ASCO Quality Care Symposium
Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.
First Author: Nicholas Moffett